UnitedHealth Raises Guidance: What It Means for XLV and Other Healthcare ETFs

UnitedHealth Group Inc. (NYSE:UNH) delivered a stronger-than-expected third-quarter earnings report and raised its full-year 2026 outlook, putting the healthcare giant back in focus for investors tracking sector ETFs. The company raised its full-year adjusted earnings guidance to at least $20.50 per share, up from its previous range of $19.50 to $20. The new minimum also tops analysts’ consensus estimate of $19.86. The results could influence sentiment toward healthcare stocks, but the implications for ETFs will depend on UnitedHealth’s portfolio weight, the performance of other holdings and whether the company’s improving profitability proves sustainable. Read Also: UnitedHealth Stock Wobbles Despite 61% Profit Jump, Boosted Outlook XLV, IHF and VHT: How Much UNH Exposure Do Investors Get? The Health Care Select Sector SPDR Fund (NYSE:XLV) offers broad exposure to large-cap U.S. healthcare companies, including pharmaceutical manufacturers, insurers and medical-device makers. UnitedHealth accounts for 5.43% of XLV’s portfolio. The iShares U.S. Healthcare Providers ETF (NYSE:IHF) offers a more concentrated route to healthcare providers and insurers. UnitedHealth represents 21.48% of the fund’s holdings, making its performance far more sensitive to UNH share movements. Meanwhile, the Vanguard Health Care ETF (NYSE:VHT) holds about 4.89% of its portfolio in UnitedHealth, along with exposure to hundreds of other healthcare companies. The comparison highlights an important distinction. IHF provides more concentrated exposure to UnitedHealth’s recovery, while XLV and VHT spread investments across a broader range of healthcare businesses. Medical Costs Remain a Key Risk UnitedHealth’s medical care ratio (MCR), which measures medical expenses as a share of premium revenue, declined to 88.4% from 89.9% a year earlier. Its operating cost ratio also improved to 12.8% from 13.5%. However, the MCR improvement included $610 million in favorable prior-period reserve development. That benefit should be separated from recurring operational improvements when assessing whether the insurer can sustain higher earnings. The company’s underlying businesses also delivered mixed results. UnitedHealthcare revenue declined to $86.3 billion from $87.1 billion a year earlier, while Optum Health revenue fell 10% to $22.9 billion. Optum Insight revenue rose 3% to $5.5 billion, and Optum Rx generated $39.9 billion. For healthcare ETF investors, the next test will be whether improved cost management translates into sustained earnings growth without further deterioration in the company’s insurance and healthcare-services operations. Bottom line: UnitedHealth’s raised guidance gives investors a fresh reason to examine healthcare ETF exposure, but the distinction between concentrated UNH exposure through IHF and broader diversification through XLV and VHT remains central to the story. Read Also: UnitedHealth Says Wall Street May Be Underestimating Its 2027 Earnings Potential Photo: Piotr Swat / Shutterstock